Testing tumour genetics in patients with cancers resistant to standard-of-care therapy

IMAGINE: Integrating Medically Actionable Genomics INto Early-phase trials

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN42303887

Enrollment

200

Registered

2020-01-13

Start date

2020-01-07

Completion date

Unknown

Last updated

2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer patients who are referred for an early-phase clinical trial. Cancer Cancer, early-phase clinical trial

Interventions

Patients that are referred to the early-phase trials clinic at the Beatson West of Scotland Cancer Centre and are assessed as being potential early-phase clinical trial participants will be given a pa

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Adult patients aged 18 years or over 2. Patients referred for an early-phase clinical trial with histologically confirmed advanced solid tumours 3. Patient meets one of the following criteria: 3.1. Willing and fit to have a tumour biopsy aimed at obtaining sufficient tissue for molecular profiling 3.2. Not willing/fit to have a tumour biopsy and had prior tumour molecular profiling 4. Patient deemed a suitable candidate for further systemic anti-cancer therapy 5. Willing and able to provide signed informed consent

Exclusion criteria

Exclusion criteria: Does not meet the inclusion criteria

Design outcomes

Primary

Measure	Time frame
To establish a mechanism and framework in which tumour samples can be obtained and molecular profiles generated in a clinically useful timeframe (<6 weeks).	—

Secondary

Measure	Time frame
1. Proportion of patients experiencing an adverse event due to tumour biopsy as measured by Common Terminology Criteria for Adverse Events (CTCAE) and calculated at 5 years 2. Proportion of patients where biopsy contained adequate tumour measured by histological observation and calculated at 5 years 3. Proportion of patients where adequate DNA was isolated using DNA isolation assay and calculated at 5 years 4. Proportion of patients where an actionable biopsy was identified by genomic analysis and calculated at 5 years 5. Proportion of patients where appropriate therapy was accessible as assessed at molecular tumour board and calculated at 5 years	—

Measure

Time frame

1. Proportion of patients experiencing an adverse event due to tumour biopsy as measured by Common Terminology Criteria for Adverse Events (CTCAE) and calculated at 5 years 2. Proportion of patients where biopsy contained adequate tumour measured by histological observation and calculated at 5 years 3. Proportion of patients where adequate DNA was isolated using DNA isolation assay and calculated at 5 years 4. Proportion of patients where an actionable biopsy was identified by genomic analysis and calculated at 5 years 5. Proportion of patients where appropriate therapy was accessible as assessed at molecular tumour board and calculated at 5 years

—

Countries

Scotland, United Kingdom

Contacts

Public ContactAnn Shaw

Ann.Shaw@glasgow.ac.uk+44 (0) 141 301 7189

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 20, 2026